A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: distribute (102), allot (2)

Papers Trust Board - 29 November 2022

Description
Date Time Location Chair Agenda Trust Board – Open Session 29/11/2022 9:00 - 13:20 Conference Room, Heartbeat/Microsoft Teams
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Trust-Board-29-November-2022.pdf

Annual-report-2018-19

Description
ANNUAL REPORT AND ACCOUNTS 2018/19 incorporating the quality account 2018/19 Presented to Parliament pursuant to Schedule 7, paragraph 25
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2018-19.pdf

Annual-report-and-quality-account-2019-20

Description
ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Trust Annual
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

RFC PO (Lite) - Cyclophosphamide-Fludarabine- Rituximab PO (Lite) Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE–FLUDARABINE–RITUXIMAB (RFC Oral Lite) Regimen Lymphoma – RFC PO (Lite) - Cyclophosphamide-Fludarabine-Rituximab PO (Lite) Indication CD20
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RFC-PO-Lite-Cyclophosphamide-Fludarabine-Rituximab-PO-Lite-Ver-1.2.pdf

RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB-VINCRISTINE (RCVP) Regimen Lymphoma – RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Indication Non-Hodgkin’s Lymphoma Toxicity
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf

RCHOP(21)-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine (21) Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE (21) (RCHOP 21) There are multiple versions of this protocol in use. Please
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCHOP21-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine-21-Ver-1.2.pdf

Lenalidomide-RituximabIV/SC

Description
Chemotherapy Protocol LYMPHOMA LENALIDOMIDE-RITUXIMAB (IV/SC) There are multiple versions of this protocol in use. Please ensure you have the
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-RituximabIVSC.pdf

Lenalidomide-Rituximab IV

Description
Chemotherapy Protocol LYMPHOMA LENALIDOMIDE-RITUXIMAB (IV) There are multiple versions of this protocol in use. Please ensure you have the correct
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-Rituximab-IV.pdf

GemP-Cisplatin-Gemcitabine-Methylprednisolone Ver 1.3

Description
Chemotherapy Protocol LYMPHOMA CISPLATIN-GEMCITABINE-METHYLPREDNISOLONE (GemP) Regimen Lymphoma – GemP-Cisplatin-Gemcitabine-Methylprednisolone Indication Non-Hodgkin’s Lymphoma Hodgkin’s Lymphoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/GemP-Cisplatin-Gemcitabine-Methylprednisolone-Ver-1.3.pdf

InP- VTD-PACE (IV) Bortezomib (IV) Cisplatin Cyclophosphamide Dexamethasone Doxorubicin Etoposide Thalidomide

Description
Chemotherapy Protocol MULTIPLE MYELOMA VTD-PACE (IV)-BORTEZOMIB (IV)-CISPLATIN-CYCLOPHOSPHAMIDEDEXAMETHASONE-DOXORUBICIN-ETOPOSIDE-THALIDOMIDE (VTD-PACE IV) In-Patient Regimen There
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/InP-VTD-PACE-IV-Bortezomib-IV-Cisplatin-Cyclophosphamide-Dexamethasone-Doxorubicin-Etoposide-Thalidomide.pdf
161 to 170 of 181
Previous … 15 16 17 18 19 Next